Targeting loss of heterozygosity for cancer-specific immunotherapy
Targeting loss of heterozygosity for cancer-specific immunotherapy
About this item
Full title
Author / Creator
Hwang, Michael S. , Mog, Brian J. , Douglass, Jacqueline , Pearlman, Alexander H. , Hsiue, Emily Han-Chung , Paul, Suman , DiNapoli, Sarah R. , Konig, Maximilian F. , Pardoll, Drew M. , Gabelli, Sandra B. , Bettegowda, Chetan , Papadopoulos, Nickolas , Vogelstein, Bert , Zhou, Shibin and Kinzler, Kenneth W.
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Developing therapeutic agents with potent antitumor activity that spare normal tissues remains a significant challenge. Clonal loss of heterozygosity (LOH) is a widespread and irreversible genetic alteration that is exquisitely specific to cancer cells. We hypothesized that LOH events can be therapeutically targeted by “inverting” the loss of an al...
Alternative Titles
Full title
Targeting loss of heterozygosity for cancer-specific immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8000272
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8000272
Other Identifiers
ISSN
0027-8424,1091-6490
E-ISSN
1091-6490
DOI
10.1073/pnas.2022410118
